Chapter 8 — Case Study 1: Stereochemistry of Drug Metabolism

"A drug is a chiral molecule with a 50% chance of doing what we want and a 50% chance of doing something else. Pharmaceutical companies invest billions of dollars in delivering only the 50% that does what we want. Yet drug metabolism in the liver can undo or invert the careful stereochemistry of synthesis." — paraphrase from a pharmacokinetics textbook

This case study explores how stereochemistry interacts with drug metabolism — how the body's enzymes can flip, racemize, or otherwise transform stereocenters during a drug's residence in the bloodstream and tissues. This has major consequences for pharmaceutical development and patient safety.

The fundamental issue

Many drugs are chiral, administered as either: - A racemic mixture (50:50 R and S). - A single enantiomer (the active form, presumably with no toxicity from the inactive form).

Once swallowed (or injected), the drug is metabolized by liver enzymes (especially cytochromes P450 and conjugation enzymes like UGTs). These enzymes are themselves chiral. Their products can be: - Same stereocenter (no change). - Inverted stereocenter (rare, but happens — the chiral inversion enzyme of ibuprofen). - Racemized (loss of stereochemistry — happens with α-carbonyl drugs via enolization). - New stereocenters introduced (during oxidation by P450 enzymes).

This means the drug a patient swallows may not be the same drug acting at the receptor. This is drug metabolism stereochemistry, and it's important.

Example 1: Ibuprofen — the stereochemical upgrade

The ibuprofen sold in pharmacies is a racemate (50:50 R and S). Only the (S) enantiomer is the pharmacologically active COX-2 inhibitor (the pain reliever). The (R) enantiomer was originally thought to be inactive.

But it's more interesting than that. (R)-Ibuprofen, in vivo, is converted to (S)-ibuprofen by a liver enzyme through chiral inversion.

The mechanism

The chiral inversion of (R)-ibuprofen involves: 1. Activation: (R)-ibuprofen is conjugated to coenzyme A (CoA) → (R)-ibuprofenyl-CoA. 2. Tautomerization at the α-carbon: the α-H is removed (the α to a thioester is acidic, pKa ~12-13), giving a planar enolate-CoA intermediate. 3. Reprotonation from the opposite face → (S)-ibuprofenyl-CoA. 4. Hydrolysis: (S)-ibuprofenyl-CoA → (S)-ibuprofen + CoA.

Net effect: (R) → (S) inversion via a planar enolate-CoA intermediate. About 60% of (R)-ibuprofen is inverted in vivo.

This stereochemical upgrade means that taking racemic ibuprofen is almost as effective as taking pure (S). The body does the work of converting (R) to (S).

Why "dexibuprofen" hasn't caught on

In the 1990s and 2000s, some companies marketed pure (S)-ibuprofen ("dexibuprofen", with "dex" loosely indicating the active form, despite (S) being levorotatory in this case). The advantages claimed: - Lower dose needed (just the active enantiomer). - Faster onset (no need to wait for chiral inversion). - Lower side effects (no inactive enantiomer).

In practice, the chiral inversion in vivo means that the racemic ibuprofen ends up doing the same job. Dexibuprofen has had only modest commercial success — racemic ibuprofen remains the standard.

Example 2: Thalidomide — the lethal racemization

The mirror-image of ibuprofen's story. (R)-thalidomide is the sedative; (S)-thalidomide is the teratogen. Pure (R)-thalidomide is racemized in vivo via a similar α-enolization mechanism.

The mechanism

Thalidomide has a chiral α-carbon (next to a C=O). The α-H is acidic (pKa ~11-13). In aqueous solution at physiological pH: 1. The α-H is removed (slowly) → planar enolate. 2. The enolate is reprotonated from either face → mixture of (R) and (S).

Half-life of racemization: hours at physiological pH.

So even if a patient is given pure (R)-thalidomide, within a few hours, ~half is converted to (S). The (S) is the teratogenic form.

Lesson: not all chiral drugs can be made safe by single-enantiomer dosing

For drugs with α-carbonyl chiral centers, racemization is unavoidable in vivo. Modern drug design avoids placing the chiral center α to a carbonyl when possible. If the chiral center is far from any carbonyl, it's stable.

Example 3: Naproxen — the dangerous mirror

Naproxen is a non-steroidal anti-inflammatory (NSAID). Like ibuprofen, only the (S) form is the active anti-inflammatory. But unlike ibuprofen: - (R)-naproxen is hepatotoxic (liver-damaging). - The chiral inversion enzyme that helps with ibuprofen does not convert (R)-naproxen to (S) at the same rate. - Therefore: naproxen must be sold as pure (S).

This is why naproxen pills are pure (S)-naproxen, while ibuprofen pills are racemate. The difference: how the body handles the (R) enantiomer.

(R)-dextromethorphan (DXM) is a cough suppressant in many cold medicines, available over the counter.

(S)-levomethorphan is an opioid analgesic and is a DEA Schedule II controlled substance in the US.

Same molecular structure, just different enantiomers. They have almost identical IR, NMR, and mass spectra. But: - The receptor for DXM is the NMDA receptor (cough suppression). - The receptor for levomethorphan is the μ-opioid receptor (analgesia, addiction, respiratory depression).

A pharmaceutical chemist must control the chirality precisely. If a synthesis of DXM accidentally gave 5% of the (S) enantiomer, the product could fail purity tests and the company could be in legal trouble.

Example 5: Omeprazole vs esomeprazole — the patent extension

In 2001, AstraZeneca's racemic omeprazole patent was about to expire. They patented esomeprazole = pure (S)-omeprazole. The (S) form has slightly different metabolism (P450 2C19 vs 3A4) and slightly better pharmacokinetics. AstraZeneca marketed it aggressively.

The science: (S)-omeprazole is the active proton-pump inhibitor. The (R) form is largely inactive. Same drug, but the patent protection of pure (S) created a new molecule.

This is sometimes called chiral switching — converting a racemic blockbuster to a pure single-enantiomer to extend the market exclusivity. It's controversial but legal.

Beyond chirality changes — drug metabolism stereochemistry

P450 enzymes oxidize drugs, sometimes introducing new stereocenters. Examples: - Codeine → morphine: P450 demethylates codeine; morphine has the same stereochemistry as codeine. - Dextromethorphan → dextrorphan: P450 demethylates DXM; the active metabolite is dextrorphan (still (R)). - Warfarin metabolism: P450 hydroxylates one face preferentially, giving stereospecific products.

These metabolic stereochemistries are critical for understanding drug-drug interactions and individual variability (some patients metabolize stereospecifically; others less so).

The lesson

Stereochemistry doesn't stop when the drug is administered. Metabolic chemistry can flip, racemize, or otherwise transform stereocenters. Modern drug design must consider: - Will the drug racemize in vivo? (α-Carbonyl chiral centers are vulnerable.) - Will the (R) form be hepatotoxic or otherwise harmful? - Can chiral inversion enzyme convert (R) to (S)? - Should we sell as racemate or pure single enantiomer? - What new stereocenters are introduced by P450 metabolism?

The answers to these questions determine whether a chiral drug is safe and effective. Chapter 27 returns to α-carbon enolization — the mechanism behind several of these examples.

Take-home

  • Drug metabolism is stereochemistry-sensitive: enzymes can flip, racemize, or transform stereocenters during the drug's residence in the body.
  • (R)-ibuprofen → (S)-ibuprofen in vivo via chiral inversion; explains why racemic ibuprofen is sold (the body upgrades the (R)).
  • (R)-thalidomide racemizes in aqueous solution via α-enolization; pure (R) dose is not safe.
  • (R)-naproxen is hepatotoxic; naproxen must be sold as pure (S).
  • Methorphan enantiomers have completely different uses (DXM cough suppressant vs levomethorphan opioid).
  • Chiral switching (omeprazole → esomeprazole) is a strategy for patent extension.
  • Modern drug design avoids α-carbonyl chiral centers when possible, to prevent racemization.
  • Mastery of Chapter 8 (mechanism + stereochemistry) is essential for understanding why some chiral drugs are safe and others are not.

Further reading

  • Caldwell, J. (1995). "Stereochemistry of Drug Metabolism." In Chirality in Drug Design and Synthesis. Academic Press.
  • Tucker, G. T. (2000). "Chiral switches." Lancet 355, 1085-1087.
  • Mehvar, R.; Brocks, D. R. (2001). "Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans." J. Pharm. Pharm. Sci. 4, 185-200.
  • Smith, S. W. (2009). "Chiral toxicology: It's the same thing... only different." Toxicol. Sci. 110, 4-30.